Business Wire

RTLS Innovator Sonitor Announces Forkbeard, the Industry’s First Ultrasound-Based Indoor Positioning Platform for Smartphones and Other Mobile Devices


Sonitor, the global leader in ultrasound-based indoor positioning technology, announced today the introduction of its groundbreaking ultrasound-based technology positioning platform named Forkbeard™.

Sonitor’s Forkbeard is the first ultrasound-based technology that enables smart mobile devices to become highly accurate indoor positioning tools offering an innovative and convenient alternative to standard RTLS tags or badges. Lyra™, the first release of this breakthrough platform, delivers never before achieved smartphone positioning accuracy enabling wayfinding to within 1 foot in a corridor, 100% room level accuracy and 1-2 second update rates. Forkbeard is compatible with the billions of iOS, Android and Windows smart devices on the market today and has been heralded by leading mobile technology insiders as a disruptive force in indoor navigation and positioning. By leveraging the capacity of the smartphone’s microphone and powerful processor, no modifications or accessories are required to transform a smartphone into an accurate positioning device or tag.

“Forkbeard represents a fundamentally new approach to ultrasound decoding developed to deliver accurate distance measurements and to find powerful Doppler effects when a device is in motion,” said Sonitor Technologies CTO and lead developer, Wilfred Booij, Ph.D. “The result is a scalable and accurate indoor positioning platform that delivers GPS-like performance indoors.”

“Forkbeard is a major technology breakthrough with applicability in healthcare and other industries, such as retail and warehousing, where reliable and accurate indoor positioning can deliver significant value,” said Anne Bugge, Sonitor Technologies, Inc. President and CEO. “With the ubiquity of consumer and professional smart devices, and the fact that we spend over 80% of our life indoors, Forkbeard has the potential to make transformative changes across multiple markets.”

“Forkbeard” (Tveskæg) was a Scandinavian king who dethroned his father, King Bluetooth (Blåtand) in 986 AD. Bluetooth was known as a unifier and communicator, and Forkbeard as a navigator and conqueror. Bluetooth® (BLE) technology was developed for short range radio communication by a special interest group initiated by Intel, Ericsson and Nokia in the 1990s and has evolved into a globally adopted short range RF communication technology. Sonitor Sense™ and Forkbeard technologies were developed for determining indoor location in complex environments. Together they outperform BLE-only technology for navigation and indoor positioning because they combine BLE with the proven accuracy of Sonitor’s patented ultrasound positioning technology.

Sonitor will be exhibiting at the HIMSS Annual Conference & Exhibition in Las Vegas, NV, March 5-9, 2018 in booth #7213 and will have live demonstrations of both the Forkbeard and Sense™ platforms.

About Sonitor

Sonitor is a leading provider and innovator of accurate and reliable ultrasound-based Real Time Location Systems (RTLS) and Indoor Positioning Systems (IPS) linking the physical world with the Internet of Things (IoT) to provide real-time visibility and connected intelligence. As the first and only company to use proprietary ultrasound technology as the primary technology for indoor positioning, Sonitor’s Sense™ and Forkbeard™ platforms work seamlessly together to help users navigate indoor environments and automatically determine the real-time location of moveable equipment and people. With its open integration platform, Sonitor provides the flexibility to leverage best-in-class software application solutions covering use cases such as wayfinding, nurse call, patient flow, workflow and capacity management, hand hygiene, infection control and asset and inventory management.

Contact information

Beacon Communications
Dan Conley, 312-593-8461

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi